Table 1. Analysis of the association of the APOBEC3B deletion with breast cancer risk using dominant model of inheritance (A3B+/− and A3B−/− vs. A3B+/+).
| group | Genotypes | No of cases(%) | No of controls(%) | OR(95%CI) | AdjustedOR(95%CI) |
|---|---|---|---|---|---|
| GDANSKBC cases (n=523)vs. unselected controls(n=853) | A3B+/+ | 450 (86.04%) | 759 (88.98%) | 1.31(0.94-1.82)p=0.11 | - |
| A3B+/− | 71 (13.58%) | 91 (10.67%) | |||
| A3B−/− | 2 (0.38%) | 3 (0.35%) | |||
| A3B+/− and A3B−/− | 73 (13.96%) | 94 (11.02%) | |||
| SZCZECINBC cases (n=2009)vs. unselected controls(n=2005) | A3B+/+ | 1764 (87.80%) | 1733 (86.43%) | 0.89(0.74-1.07)p=0.20 | 0.90(0.75-1.08)ap=0.26 |
| A3B+/− | 235 (11.70%) | 267 (13.32%) | |||
| A3B−/− | 10 (0.50%) | 5 (0.25%) | |||
| A3B+/− and A3B−/− | 245 (12.20%) | 272 (13.57%) | |||
| SZCZECINBC cases (n=2009)vs. NH-controls (n=615) | A3B+/+ | 1764 (87.80%) | 542 (88.13%) | 1.03(0.78-1.36)p=0.83 | 0.95(0.70-1.29)ap=0.73 |
| A3B+/− | 235 (11.70%) | 68 (11.06%) | |||
| A3B−/− | 10 (0.50%) | 5 (0.81%) | |||
| A3B+/− and A3B−/− | 245 (12.20%) | 73 (11.87%) | |||
| GDANSK+SZCZECINBC cases (n=2532)vs. unselected controls(n=2858) | A3B+/+ | 2214 (87.44%) | 2492 (87.19%) | 0.98(0.83-1.15)p=0.79 | 0.97(0.83-1.14)bp=0.73 |
| A3B+/− | 306 (12.09%) | 358 (12.53%) | |||
| A3B−/− | 12 (0.47%) | 8 (0.28%) | |||
| A3B+/− and A3B−/− | 318 (12.56%) | 366 (12.81%) | |||
| GDANSK+SZCZECINfamilial BC cases (n=640)vs. unselected controls(n=2858) | A3B+/+ | 554 (86.56%) | 2492 (87.19%) | 1.06(0.82-1.36)p=0.67 | 1.15(0.87-1.52)bp=0.32 |
| A3B+/− | 84 (13.13%) | 358 (12.53%) | |||
| A3B−/− | 2 (0.31%) | 8 (0.28%) | |||
| A3B+/− and A3B−/− | 86 (13.44%) | 366 (12.81%) |
aAdjusted for age; badjusted for the origin of the study.